IL-4/IL-13应答性IGFLs促进过敏性皮肤炎症的证据
该研究探讨IGFL家族成员在过敏性皮肤炎症中的作用。研究发现IGFL1和IGFL4在特应性皮炎(AD)皮损中显著升高,小鼠Igfl在噁唑酮诱导的过敏性皮肤炎症模型中显著升高;Igfl缺陷小鼠疾病严重程度标志物显著降低,且Il4、Il13等2型炎症转录本减少。IL-4或IL-13可促进小鼠角质形成细胞表达Igfl,IL-4Rα依赖Igfl诱导,接受度普利尤单抗或曲罗芦单抗治疗的AD患者皮损IGFL4表达下降。
要点
- IGFL1/IGFL4在AD皮损中显著升高,小鼠Igfl在过敏性皮肤炎症模型中升高
- Igfl缺陷减轻小鼠过敏性皮肤炎症及2型炎症转录本
- IL-4/IL-13通过IL-4Rα诱导角质形成细胞IGFL表达,形成正反馈环
核心结论
- IL-4/IL-13与IGFLs之间存在正反馈环,可促进过敏性皮肤炎症。
研究设计与样本
- 研究采用AD患者皮损样本、噁唑酮诱导的小鼠过敏性皮肤炎症模型及Igfl缺陷小鼠。
- 通过RNA测序和qPCR检测转录本,并利用小鼠和人类角质形成细胞进行刺激实验。
- 体内实验分析IL-4Rα依赖性,并观察接受度普利尤单抗或曲罗芦单抗治疗的AD患者皮损IGFL4表达变化。
主要发现
- IGFL1和IGFL4在AD皮损中显著增加,小鼠Igfl在Oxa诱导模型中显著增加。
- Igfl缺陷小鼠疾病严重程度标志物显著降低,Il4、Il13及其他2型炎症相关转录本减少。
- Oxa模型中Il4先于Igfl诱导,小鼠角质形成细胞是Igfl来源,IL-4或IL-13刺激促进Igfl表达而IFNγ无此作用。
- IL-4或IL-13刺激人类角质形成细胞诱导IGFL4。
- Igfl诱导依赖IL-4Rα,接受度普利尤单抗或曲罗芦单抗治疗的AD患者皮损IGFL4表达降低。
关键数值与推荐
- IGFL1和IGFL4在AD皮损中显著增加(原文未报告具体数值)。
- Igfl缺陷小鼠疾病严重程度标志物显著降低(原文未报告具体数值)。
- IL-4或IL-13刺激促进小鼠角质形成细胞Igfl表达,IFNγ无此作用。
- 接受度普利尤单抗或曲罗芦单抗治疗的AD患者皮损IGFL4表达降低。
临床怎么用
- 提示IL-4/IL-13应答性IGFLs可能作为过敏性皮肤炎症的生物标志物或治疗靶点。
- 度普利尤单抗或曲罗芦单抗治疗可降低AD皮损IGFL4表达,支持其机制涉及IGFLs通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IGF-Like (IGFL) Family member proteins are a putative cytokine family whose functions are not defined. Here we demonstrate that IGFL1 and IGFL4 are significantly increased in lesional atopic dermatitis (AD) skin and mouse Igfl is significantly increased in an oxazolone (Oxa)-induced model of allergic skin inflammation. In addition, studies with Igfl-deficient mice revealed significant reductions in markers of disease severity. RNA sequencing and qPCR demonstrated reduced Il4, Il13, and other type 2 inflammation-associated transcripts in Oxa treated skin from Igfl-deficient mice. As the Oxa model is Th2 cytokine-dependent, we hypothesized IL-4 and/or IL-13 promote Igfl expression. In support of this, we discovered Il4 precedes Igfl induction in the Oxa model. We then identified mouse keratinocytes as a source of Igfl and found stimulation with IL-4 or IL-13 promoted Igfl expression in these cells, while IFNγ did not. Stimulation of human keratinocytes with IL-4 or IL-13 induced IGFL4. In vivo experiments also demonstrated that Igfl induction is dependent on IL-4Rα in the Oxa model, and AD patients who received dupilumab or tralokinumab treatment showed decreased IGFL4 expression in lesional skin. These data suggest there is a positive feedback loop between IL-4/IL-13 and IGFLs that can promote allergic skin inflammation.
引用
- Wang Q, Xue GR, Zhou HM, et al. Evidence that IL-4/IL-13-Responsive IGFLs Promote Allergic Skin Inflammation. J Invest Dermatol. 2026. PMID: 42815711. doi:10.1016/j.jid.2026.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。